Tempest Therapeutics Inc expected to post a loss of $2.60 a share - Earnings Preview
RefinitivLess than 1 min read
Tempest Therapeutics Inc
TPST is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of $2.60 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tempest Therapeutics Inc is $9.00, about 16.8% above its last closing price of $7.49
Login or create a forever free account to read this news